DudeDiligence.

THE WIRE

What insiders and companies just did: insiders buying and selling with their own money, company news, new 5% stakes and new shares registered.

BoughtSoldSold under a plan set in advanceCompany newsA 5% stakeNew shares registeredThe stock since the filing

Key

BoughtSoldSold under a plan set in advanceCompany newsA 5% stakeNew shares registeredThe stock since the filing

Newest first. Insider rows are open-market purchases and sales; several by one company are one row, open it for each.

  1. AGCOAgco CorpThe SVP GM Fendt/Valtra sold $3.1M of stock.$3.1M−13.1%Form 4 ↗
  2. HIVEHIVE Digital Technologies LtdResults of operations.−36.2%8-K 2.02 ↗
  3. CRHCRH Public LTD CoA director bought $570K of stock.$570K−9.5%Form 4 ↗
  4. KLRSKalaris Therapeutics, IncResults of operations.−44.3%8-K 2.02 ↗
  5. MIRMMirum Pharmaceuticals, IncOther events.+3.2%8-K 8.01 ↗
  6. MCFTMasterCraft Boat Holdings, IncResults of operations.MasterCraft Boat Holdings, Inc. Reports Results for the First Three Months of Its Transition Period+4.0%8-K 2.02 ↗
  7. ECCEagle Point Credit CoOther events.+8.0%8-K 8.01 ↗
  8. XLOXilio Therapeutics, IncResults of operations.−16.0%8-K 2.02 ↗
  9. CDXSCodexis, IncMaterial agreement and unregistered sale of shares.−9.0%8-K 1.01 ↗
  10. XGNExagen IncResults of operations.−49.2%8-K 2.02 ↗
  11. LCIILci IndustriesOther events.−2.4%8-K 8.01 ↗
  12. AMBQAmbiq Micro, IncResults of operations.Ambiq Reports Third Quarter 2026 Financial Results Third quarter net sales increased 110% year-over-year on broad demand across customers, product families and form factors Gross profit more than…−13.3%8-K 2.02 ↗
  13. ENTGEntegris IncRegulation FD disclosure and other events.Board authorizes $500 million share repurchase program−11.1%8-K 7.01 ↗
  14. GERNGeron CorpPassive stake of 5% or more (13G), filed by State Street.−12.6%13G ↗
  15. ABUSArbutus Biopharma CorpResults of operations.+8.1%8-K 2.02 ↗
  16. TROXTronox Holdings plcA director bought $53K of stock.$53K−45.5%Form 4 ↗
  17. KUSTKustom Entertainment, IncResults of operations and Regulation FD disclosure.KUSTOM ENTERTAINMENT, INC. ANNOUNCES THIRD QUARTER OPERATING RESULTS REVENUE UP 57%, NET INCOME REACHES $2.3 MILLION AND STOCKHOLDERS’ EQUITY MORE THAN TRIPLED SINCE YEAR END 2025 AS THE COMPANY…−25.4%8-K 2.02 ↗
  18. FTDRFrontdoor, IncPassive stake of 5% or more (13G), filed by State Street.−11.6%13G ↗
  19. FOXAFox CorpPassive stake of 5% or more (13G), filed by State Street.−7.1%13G ↗
  20. FOXAFox CorpPassive stake of 5% or more (13G), filed by State Street.−7.1%13G ↗
  21. EFOIEnergy Focus, IncResults of operations.Energy Focus, Inc. Reports Third Quarter 2026 Financial Results−32.4%8-K 2.02 ↗
  22. FETForum Energy Technologies, IncPassive stake of 5% or more (13G), filed by State Street.−3.1%13G ↗
  23. CLRBCellectar Biosciences, IncResults of operations.−37.7%8-K 2.02 ↗
  24. AUTLAutolus Therapeutics plcResults of operations and Regulation FD disclosure.−31.3%8-K 2.02 ↗
  25. FMCFMC CorpPassive stake of 5% or more (13G), filed by State Street.−28.1%13G ↗
  26. CMCCOMMERCIAL METALS CoOfficer or director change and Regulation FD disclosure.CMC Announces CFO Retirement and Succession Plan; Appoints Kenji Hashimoto as Deputy CFO−15.4%8-K 5.02 ↗
  27. FISFidelity National Information Services, IncPassive stake of 5% or more (13G), filed by State Street.−8.9%13G ↗
  28. FBKFB Financial CorpPassive stake of 5% or more (13G), filed by State Street.−7.0%13G ↗
  29. XOMExxonMobil Holdings CorpPassive stake of 5% or more (13G), filed by State Street.−2.3%13G ↗
  30. EXPEExpedia Group, IncPassive stake of 5% or more (13G), filed by State Street.−9.2%13G ↗
  31. MRAMEverspin Technologies IncPassive stake of 5% or more (13G), filed by State Street.−30.3%13G ↗
  32. EPREpr PropertiesPassive stake of 5% or more (13G), filed by State Street.−3.6%13G ↗
  33. ECHOEchoStar CORPPassive stake of 5% or more (13G), filed by State Street.−16.7%13G ↗
  34. EBCEastern Bankshares, IncPassive stake of 5% or more (13G), filed by State Street.−8.5%13G ↗
  35. EGBNEagle Bancorp IncPassive stake of 5% or more (13G), filed by State Street.−4.4%13G ↗
  36. CALCCalciMedica, IncResults of operations.CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both…−16.8%8-K 2.02 ↗
  37. DDDuPont de Nemours, IncPassive stake of 5% or more (13G), filed by State Street.−6.3%13G ↗
  38. DLTRDollar Tree, IncPassive stake of 5% or more (13G), filed by State Street.+0.5%13G ↗
  39. SRRKScholar Rock Holding CorpMaterial agreement and results of operations.−6.6%8-K 1.01 ↗
  40. LNSRLENSAR, IncResults of operations.−18.3%8-K 2.02 ↗
  41. DXCMDexcom IncPassive stake of 5% or more (13G), filed by State Street.−2.2%13G ↗
  42. COAGHemab Therapeutics Holdings, IncResults of operations.Expects to present data from the ongoing VELORA Pioneer Phase 1/2 trial of HMB-002 in Von Willebrand Disease at the 20th EAHAD (European Association for Haemophilia and Allied Disorders) Congress in…−8.2%8-K 2.02 ↗
  43. DKDelek US Holdings, IncPassive stake of 5% or more (13G), filed by State Street.−7.6%13G ↗
  44. CTYCity Therapeutics, IncRegulation FD disclosure.City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide…8-K 7.01 ↗
  45. PDYNPalladyne AI CorpResults of operations and Regulation FD disclosure.Palladyne AI Reports Record Third Quarter 2026 Results Revenue increased 895% year-over-year and 48% sequentially to $8.6 million Raises bottom end of full-year 2026 revenue guidance to $25 million…−33.1%8-K 2.02 ↗
  46. DCDakota Gold CorpPassive stake of 5% or more (13G), filed by State Street.−36.3%13G ↗
  47. CGEMCullinan Therapeutics, IncResults of operations.−24.2%8-K 2.02 ↗
  48. SIONSionna Therapeutics, IncResults of operations.−20.9%8-K 2.02 ↗
  49. UPBUpstream Bio, IncResults of operations.Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress - Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 -…−55.6%8-K 2.02 ↗
  50. OLMAOlema Pharmaceuticals, IncResults of operations.−4.6%8-K 2.02 ↗